Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

PHOENIX – A long-time leader in iron innovation and performance, today PING introduced the Blueprint S and Blueprint T, two new forged iron models engineered and custom-built for golfers seeking ...

Blueprint was prepared to spend $5,537,927 on the redesign. It is unclear where these funds will be shifted to now. The agency is still eager to work something out with FDOT if possible, but the ...

He believes the Blueprint will be further adjusted during next year’s legislative session in 2026. But only slightly. He says the big changes will come in 2027 after next year’s mid-term ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

The two companies said on Monday that Sanofi would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade.